Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Other anti-obesity medications
6 evidence topics · 6 sources
AGA guideline recommendations for pharmacotherapy
“The panel strongly recommended the use of pharmacotherapy in addition to lifestyle intervention in adults with overweight and obesity (body mass index ≥30 kg/m2, or ≥27 kg/m2 with weight-related complications) who have an inadequate response to lifestyle interventions.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The panel suggested the use of semaglutide 2.4 mg, liraglutide 3.0 mg, phentermine-topiramate ER, and naltrexone-bupropion ER (based on moderate certainty evidence), and phentermine and diethylpropion (based on low certainty evidence), for long-term management of overweight and obesity.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The guideline panel suggested against the use of orlistat.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Endocrine Society guideline on medications as adjuncts to lifestyle change
Weight loss with older anti-obesity medications in the ADA Standards of Care
| Medication | Active treatment arm; weight loss from baseline | Placebo; weight loss from baseline | Trial duration (weeks) |
|---|---|---|---|
| Phentermine | “15 mg q.d.; 7.4%”View highlighted excerpt for this quote | “Placebo; 2.3%”View highlighted excerpt for this quote | “28”View highlighted excerpt for this quote |
| Phentermine/topiramate ER | “15 mg/92 mg q.d.; 9.8%”View highlighted excerpt for this quote | “Placebo; 1.2%”View highlighted excerpt for this quote | “56”View highlighted excerpt for this quote |
| Naltrexone/bupropion ER | “16 mg/180 mg b.i.d.; 5%”View highlighted excerpt for this quote | “Placebo; 1.8%”View highlighted excerpt for this quote | “56”View highlighted excerpt for this quote |
| Orlistat | “120 mg t.i.d.; 9.6%”View highlighted excerpt for this quote | “Placebo; 5.6%”View highlighted excerpt for this quote | “52”View highlighted excerpt for this quote |
Duration of approval for phentermine and other older adrenergic agents
“Phentermine and other older adrenergic agents are approved for short-term treatment (112), while all others are approved for long-term treatment (Tables 8.1 and 8.2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“As monotherapy, phentermine is only approved for short-term use.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Phentermine plus topiramate: CONQUER primary results at week 56
“At 56 weeks, change in bodyweight was -1·4 kg (least-squares mean -1·2%, 95% CI -1·8 to -0·7), -8·1 kg (-7·8%, -8·5 to -7·1; p<0·0001), and -10·2 kg (-9·8%, -10·4 to -9·3; p<0·0001) in the patients assigned to placebo, phentermine 7·5 mg plus topiramate 46·0 mg, and phentermine 15·0 mg plus topiramate 92·0 mg, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The most common adverse events were dry mouth (24 [2%], 67 [13%], and 207 [21%] in the groups assigned to placebo, phentermine 7·5 mg plus topiramate 46·0 mg, and phentermine 15·0 mg plus topiramate 92·0 mg, respectively), paraesthesia (20 [2%], 68 [14%], and 204 [21%], respectively)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Naltrexone plus bupropion: COR-I primary results at week 56
“Mean change in bodyweight was -1.3% (SE 0.3) in the placebo group, -6.1% (0.3) in the naltrexone 32 mg plus bupropion group (p<0.0001 vs placebo) and -5.0% (0.3) in the naltrexone 16 mg plus bupropion group (p<0.0001 vs placebo).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“870 (50%) participants completed 56 weeks of treatment (n=296; n=284; n=290, respectively)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote